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1018Comparison of Outcomes after Transplantation of
G-CSF–Stimulated Bone Marrow Grafts versus Bone
Marrow or Peripheral Blood Grafts from HLA-Matched
Sibling Donors for Patients with Severe
Aplastic Anemia
Roland Chu,1 Ruta Brazauskas,2 Fangyu Kan,3 Asad Bashey,4 Christopher Bredeson,2
Bruce Camitta,2 Kuang-Yueh Chiang,5 Haydar Frangoul,6 Robert Peter Gale,7 Adrian Gee,8
Biju George,9 Frederick D. Goldman,10 Thomas G. Gross,11 Vikas Gupta,12
Gregory A. Hale,13 Luis Isola,14 Alvaro Urbano Ispizua,15 Hillard Lazarus,16 Judith Marsh,17
James Russell,18 Mitchell Sabloff,19 Edmund K. Waller,5 Mary Eapen2We compared outcomes of patients with severe aplastic anemia (SAA) who received granulocyte-colony
stimulating factor (G-CSF)–stimulated bone marrow (G-BM) (n 5 78), unstimulated bone marrow (BM)
(n 5 547), or peripheral blood progenitor cells (PBPC) (n 5 134) from an HLA-matched sibling. Transplan-
tations occurred in 1997 to 2003. Rates of neutrophil and platelet recovery were not different among the 3
treatment groups. Grade 2-4 acute graft-versus-host disease (aGVHD) (relative risk [RR]5 0.82, P5 .539),
grade 3-4 aGVHD (RR 5 0.74, P 5 .535), and chronic GVHD (cGVHD) (RR 5 1.56, P 5 .229) were similar
after G-BM and BM transplants. Grade 2-4 aGVHD (RR5 2.37, P5 .012) but not grade 3-4 aGVHD (RR5
1.66, P 5 .323) and cGVHD (RR 5 5.09, P\.001) were higher after PBPC transplants compared to G-BM.
Grade 2-4 (RR5 2.90, P\.001), grade 3-4 (RR5 2.24, P5.009) aGVHD and cGVHD (RR5 3.26, P\.001)
were higher after PBPC transplants compared to BM. Mortality risks were lower after transplantation of BM
compared to G-BM (RR5 0.63, P5 .05). These data suggest no advantage to using G-BM and the observed
higher rates of aGVHD and cGVHD in PBPC recipients warrants cautious use of this graft source for SAA.
Taken together, BM is the preferred graft for HLA-matched sibling transplants for SAA.
Biol Blood Marrow Transplant 17: 1018-1024 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: G-mobilized BM, GVHD, Aplastic anemia, SurvivalINTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
is the treatment of choice for patients with severe
aplastic anemia (SAA) when a HLA-matched sibling
donor is available. Recent years have seen increasing
use of hematopoietic cells other than bone marrow
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graft-versus-host disease (GVHD) [4-6]. Others
have examined transplant outcomes after G-BM in
transplantation for hematologic malignancies [7-9].
Results show similar rates of hematopoietic recovery
and lower acute and chronic GVHD (aGVHD,
cGVHD) after G-BM and PBPC transplants [10,11].
Use of PBPC fromHLA-matched siblings for SAA is
associated with higher risks of cGVHD, and in children,
highermortality compared toBM[12].Todate, there are
no reports that have compared use of G-BM for SAA to
BM or PBPC. Therefore, we report on transplant out-
comes afterG-BM (n5 78) compared to BM transplants
(n 5 547), and G-BM compared to PBPC (n 5 134)
transplants reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR).PATIENTS AND METHODS
Data Source
Patient, disease, and transplant characteristics and
outcome data were reported to the Center for Interna-
tional Blood and Marrow Transplant Research. The
CIBMTRis a voluntaryworkinggroupofover 400 trans-
plant centers worldwide that contribute data on consecu-
tivehematopoietic transplantations to aStatisticalCenter
at theMedicalCollege ofWisconsin. Participating trans-
plant centers are required to register all consecutive
transplantation and detailed patient, disease, and trans-
plant characteristics and outcome data are collected on
a subset of registered transplantations using a weighted
randomized scheme. The study population includes
only patients selected for detailed reporting. Compliance
anddataquality aremonitoredbyon-site audits, comput-
erized error checks, and physician review of submitted
data. All patients are followed longitudinally, annually.
This study was approved by the Institutional Review
Board of the Medical College of Wisconsin.
Inclusion Criteria
Included are patients who underwent an HLA-
matched sibling transplantation for SAA. The diagnos-
tic criteria of SAA are similar to those of Camitta et al.
[13], modified so that a marrow with\50% cellularity
and\30% hematopoietic cells also satisfies the criteria
formarrowaplasia (in addition to the original criteria of
\25% cellularity). All transplantations occurred in
1997 to 2003. Seventy-eight patients received G-BM
grafts, 547patients receivedBMgrafts, and134patients
received PBPC grafts. Excluded were patients older
than 50 years, recipients of cord blood grafts, and
T cell–depleted BM or CD34-selected PBPC grafts.
Endpoints
Neutrophil recovery was defined as achieving an ab-
solute neutrophil count$0.5 109/L for 3 consecutivedays, and platelet recovery $20  109/L for 7 days,
unsupported.Grades 2-4 and3-4 aGVHDand cGVHD
were determined using standard criteria [14,15]. Overall
mortality was defined as death from any cause.
Statistical Analysis
Patient-, disease-, and transplant-related variables
are shown in Table 1. Characteristics of the 3 groups
were compared between the 3 groups using the chi-
square statistic for categoric variables and the Kruskal-
Wallis test for continuous variables [16]. Probabilities
of overall survival (OS) were calculated using Kaplan-
Meier estimator. Cumulative incidence rates for neutro-
phil and platelet recovery and aGVHD and cGVHD
were calculated using standard techniques [16]; for neu-
trophil and platelet recovery and aGVHDand cGVHD,
death without an event was the competing risk. Ninety-
five percent confidence intervals (CIs) were calculated
using the standard error of the survival function ob-
tained by Greenwood formula. Adjusted probability of
OS was estimated using the Cox proportional hazards
method to adjust for patient-, disease-, and transplant-
related variables included in the final multivariate
models. Logistic regression was employed to model
the probability of neutrophil recovery at 30 days and
platelet recovery at 100 days after the transplantation.
Multivariate models were built using the backward
selection method with a significance level of 0.05. The
primary objective of this study was to compare the out-
comes after G-BM, BM, and PBPC transplantation.
Therefore, the variable for graft type (G-BM versus
BM versus PBPC) was held in all steps of model build-
ing and independent of level of significance. Other
variables considered were recipient age, performance
score, time from diagnosis until transplant (#6months
versus .6 months), number of red blood cell transfu-
sions prior to transplantation (#20 versus .20 versus
not reported), inclusion of ATG in conditioning regi-
men, use of hematopoietic growth factor within first 7
days of transplantation, sex of recipient and donor,
cytomegalovirus (CMV) serostatus of donor and recip-
ient, and year of transplantation. In Cox models, all
variables met the proportional hazards assumption
that was tested by using a time-varying covariate
method. First-order interactions between graft type
and each variable of interest were examined by fitting
the proportional hazards model, and examining the in-
teraction between the variable of interest and graft
type. All the P-values are 2-sided. Analyses were per-
formed using SAS software, version 9.1 (SAS Institute,
Cary, NC).RESULTS
Patient, disease, and transplant characteristics are
presented in Table 1. All aspects of the transplant
Table 1. Patient, Disease, and Transplant Characteristics
BM G-BM PBPC
Variables Number (%) Number (%) Number (%) P Value
Total number 547 78 134
Sex, male 323 (59) 49 (63) 75 (56) .614
Recipient age < .001
#10 years 114 (21) 5 (6) 7 (5)
11-20 years 206 (38) 20 (26) 38 (28)
21-30 years 123 (22) 28 (36) 47 (35)
31-40 years 73 (13) 16 (21) 24 (18)
41-50 years 31 (6) 9 (12) 18 (13)
Performance score prior to transplant .055
<90 191 (35) 23 (29) 59 (44)
90-100 350 (64) 55 (71) 73 (54)
Not reported 6 (1) __ 2 (1)
Time from diagnosis to transplant < .001
#6 months 409 (75) 46 (59) 67 (50)
>6 months 138 (25) 32 (41) 67 (50)
Number of red blood cell transfusions < .001
None 25 (5) 14 (18) 13 (10)
#20 200 (37) 27 (35) 57 (42)
>20 240 (44) 30 (38) 41 (31)
Not reported 95 (17) 20 (26) 34 (25)
Conditioning regimen < .001
Cyclophosphamide alone 88 (16) 7 (9) 22 (16)
Cyclophosphamide + ATG 313 (57) 53 (68) 68 (51)
Cyclophosphamide + busulfan ± other 111 (20) 12 (15) 7 (5)
Cyclophosphamide + limited field irradiation ± ATG 19 (3) 2 (3) 3 (2)
Cyclophosphamide + fludarabine ± other 7 (1) 1 (1) 17 (13)
Other 9 (2) 3 (4) 17 (13)
Graft-versus-host disease prophylaxis < .001
Cyclosporine ± other 46 (8) 5 (6) 50 (37)
Cyclosporine + methotrexate ± other 485 (89) 68 (87) 80 (60)
Tacrolimus ± other 7 (1) 2 (3) 3 (2)
Other 9 (2) 3 (4) 1 (1)
Use of hematopoietic growth factor within 7 days posttransplant < .001
No 380 (69) 31 (40) 54 (40)
Yes 162 (30) 47 (60) 80 (60)
Not reported 5 (1) 0 0
Donor-recipient sex match .008
Male donor to male recipient 191 (35) 16 (21) 41 (31)
Male donor to female recipient 127 (23) 21 (27) 30 (22)
Female donor to male recipient 132 (24) 33 (42) 34 (25)
Female donor to female recipient 97 (18) 8 (10) 29 (22)
Donor-recipient CMV serostatus .509
Donor negative/recipient negative 122 (22) 15 (19) 35 (26)
Donor negative/recipient positive 71 (13) 11 (14) 17 (13)
Donor positive/recipient negative 24 (4) 6 (8) 4 (3)
Donor positive/recipient positive 299 (55) 39 (50) 74 (55)
Not reported 31 (6) 7 (9) 4 (3)
Year of transplant < .001
1997-1999 281 (51) 31 (40) 41 (31)
2000-2003 266 (49) 47 (60) 93 (69)
Follow-up of surviving patients, median (range) months 62 (3-125) 45 (3-123) 51 (3-119)
CMV indicates cytomegalovirus; PBPC, peripheral blood progenitor cells; G-BM, granulocyte bone marrow; BM, bone marrow; ATG, antithyrocyte
globulin.
1020 Biol Blood Marrow Transplant 17:1018-1024, 2011R. Chu et al.regimen, including choice of graft, were at the discre-
tion of the transplant center. Groups were similar in
terms of patient sex, performance score, conditioning
regimen, and GVHD prophylaxis. There were signif-
icant differences in the age of patients receiving G-
BM, BM, and PBPC. G-BM and PBPC recipients
were older, with median ages of 25 years and 24 years,
respectively, compared to BM recipients, whose me-
dian age was 18 years (P\ .001). Most patients re-
ceived cyclophosphamide alone or cyclophosphamide
with antithymocyte globulin (ATG) for transplantconditioning and calcineurin-inhibitor containing
GVHD prophylaxis. The median follow-up of surviv-
ing patients is 4 years after G-BM transplants and 5
years after BM and PBPC transplants.Hematologic Recovery
The median times to neutrophil recovery were 15
days, 20 days, and 13 days after G-BM, BM, and
PBPC transplantations, respectively. Althoughmedian
recovery times were faster after transplantation of
Biol Blood Marrow Transplant 17:1018-1024, 2011 1021G-Mobilized BM for Aplastic AnemiaG-BM and PBPC compared to BM (P\ .001), the
cumulative incidence of neutrophil recovery at day
30 was similar after transplantation of G-BM, BM,
and PBPC: 91% (95% confidence interval [CI],
84%-96%), 90% (95% CI, 87%-92%), and 93%
(95% CI, 88%-97%), respectively (P 5 .378). In mul-
tivariate analysis, the likelihood of achieving neutro-
phil recovery at 30 days after transplantation was
similar in the 3 groups (Table 2A). The likelihood of
neutrophil recovery was higher with addition of
ATG to conditioning regimen (odds ratio [OR] 1.87,
95% CI 1.14-3.07, P 5 .013) compared to regimens
without ATG and when the interval between diagnosis
and transplantation was longer than 6 months (OR
2.21, 95% CI 1.17-4.17, P 5 .014).
Platelet recovery after transplantation of G-BM
was slower compared to BM (P 5 .015) and PBPC
(P \ .001). Median times to platelet recovery were
31 days, 26 days, and 19 days after BM, G-BM, and
PBPC transplantation, respectively. However, by day
60, the cumulative incidence of platelet recovery after
G-BM, BM, and PBPC transplantation were 86%
(95% CI, 77%-93%), 85% (95% CI, 82%-88%),
and 83% (95% CI, 77%-89%), respectively (P 5
.742). In multivariate analysis, the likelihood of plate-
let recovery at day 30 after transplantation was similar
in the 3 groups (Table 2A). The likelihood of platelet
recovery was lower in patients with performance score
\90 (OR 0.50, 95% CI 0.32-0.78, P 5 .002).Acute GVHD and cGVHD
Cumulative incidence of grades 2-4 aGVHD at
day 100 were 14% (95% CI 8%-23%), 13% (95%
CI 10%-16%), and 28% (95% CI 20%-35%) after
G-BM, BM, and PBPC transplantation, respectively.
The corresponding cumulative incidence of grades
3-4 acute GVHD were 6% (95% CI 2%-13%), 6%
(95%CI 4%-8%), and 12% (95%CI 7%-18%). Com-
pared to G-BM transplants, the risk of grade 2-4 and
3-4 aGVHD were similar after BM transplants
(Table 2B). Grade 2-4 aGVHD but not grade 3-4
aGVHDwas higher after PBPC transplants comparedTable 2A. Risk Factors Associated with Hematopoietic
Recovery
Outcome
Odds Ratio
(95% Confidence Interval) P Value
Neutrophil recovery at day 30
BM versus G-BM 1.07 (0.46-2.47) .877
PBPC versus G-BM 1.30 (0.46-3.67) .626
PBPC versus BM 1.21 (0.57-2.57) .614
Platelet recovery at day 100
BM versus G-BM 0.97 (0.47-2.03) .943
PBPC versus G-BM 0.91 (0.40-2.08) .821
PBPC versus BM 0.93 (0.53-1.65) .813
PBPC indicates peripheral blood progenitor cells; G-BM, granulocyte
bone marrow; BM, bone marrow.to G-BM transplants (Table 2B). Grade 2-4 and 3-4
aGVHD were higher after PBPC transplants com-
pared to BM transplants (Table 2B). Use of ATG
was associated with lower acute grade 2-4 (relative
risk [RR] 0.64, 95% CI 0.44-0.92, P5 .015) and grade
3-4 aGVHD (RR 0.50, 95% CI 0.29-0.86, P 5 .012).
Performance score \90 was associated with higher
risks of grade 3-4 aGVHD (RR 3.06, 95% CI
1.75-5.35, P\ .001).
Cumulative incidence of cGVHD at 3 years as
10% (95% CI 4%-17%), 16% (95% CI 13%-19%),
and 43% (95% CI 35%-52%) after G-BM, BM, and
PBPC transplantation, respectively. Compared to G-
BM transplants, cGVHD risks were similar after BM
transplants but higher after PBPC transplants (Table
2B). Chronic GVHD was also higher after PBPC
transplants compared to BM transplants. Chronic
GVHD was higher in patients aged 35 years or older
(RR 1.61, 95% CI 1.09-2.37, P 5 .015).
As approximately 60% of BM recipients compared
to a third of G-BM and PBPC recipients were aged
\21 years, we performed a subset analysis restricting
to patients 21 years and older. Consistent with the
main analysis, risks of grade 2-4 aGVHD were higher
after transplantation of PBPC compared toG-BM (RR
2.36, 95% CI 1.08-5.19, P 5 .032) and BM (RR 2.09,
95% CI 1.28-3.39, P 5 .003). Similarly, risks of
cGVHD were also higher after transplantation of
PBPC compared to G-BM (RR 5.52, 95% CI 2.35-
12.97, P \ .001) and BM (RR 2.62, 95% CI 1.75-
3.94, P\ .001).OS
Risks of overall mortality were similar after trans-
plantation of G-BM compared to PBPC and BM com-
pared to PBPC (Table 2B). However, mortality risks
were lower after transplantation of BM compared to
G-BM. Mortality risks were similar after PBPC and
BM transplants. Mortality risks for all patients were
lower with inclusion of ATG in conditioning regimen
(RR 0.53, 95% CI 0.39-0.72, P\ .001), performance
score 90-100 (RR 0.54, 95% CI 0.39-0.73, P\ .001),
and patients younger than 35 years (RR 0.51, 95%
CI 0.37-0.72, P\ .001). The 3-year probabilities of
OS adjusted for ATG, performance score, and patient
age were 80%, 72%, and 76% after BM, G-BM, and
PBPC transplantation, respectively (Figure 1). In sub-
set analysis restricted to patients aged 21 years and
older, after adjusting for patient age, mortality risks
are similar after transplantation of G-BM compared
to BM (RR 0.94, 95% CI 0.53-1.70, P5 .856). As ob-
served in themain analysis, patients older than 35 years
and those with performance scores\90 were at higher
risk of mortality.
The causes of death are shown in Table 3. One
hundred eighteen BM recipients (21%), 22 G-BM
Table 2B. Risk Factors Associated with aGVHD and cGVHD
and Overall Survival
Variable
Relative Risk
(95% Confidence Interval) P Value
Grade 2-4 aGVHD
BM versus G-BM 0.82 (0.43-1.55) .539
PBPC versus G-BM 2.37 (1.21-4.64) .012
PBPC versus BM 2.90 (1.95-4.31) < .001
Grade 3-4 aGVHD
BM versus G-BM 0.74 (0.29-1.91) .535
PBPC versus G-BM 1.66 (0.61-4.56) .323
PBPC versus BM 2.24 (1.23-4.10) .009
Chronic GVHD
BM versus G-BM 1.56 (0.76-3.24) .229
PBPC versus G-BM 5.09 (2.42-10.69) < .001
PBPC versus BM 3.26 (2.31-4.60) < .001
Overall mortality
BM versus G-BM 0.63 (0.40-1.00) .050
PBPC versus G-BM 0.80 (0.47-1.37) .424
PBPC versus BM 1.28 (0.87-1.88) .212
PBPC indicates peripheral blood progenitor cells; G-BM, granulocyte
bone marrow; BM, bone marrow; aGVHD, acute graft-versus-host
disease; cGVHD, chronic graft-versus-host disease.
1022 Biol Blood Marrow Transplant 17:1018-1024, 2011R. Chu et al.(28%), and 37 PBPC (28%) are death. Graft failure,
organ failure, andGVHDwere common in the 3 treat-
ment groups. Death from infection was higher after
BM and G-BM transplants, and interstitial pneumoni-
tis was higher after PBPC transplants.DISCUSSION
The primary objective of the current analysis was
to compare rates of aGVHD and cGVHD and OS
after transplantation of G-BM to BM and PBPC
from an HLA-matched sibling for SAA. Compared
to G-BM transplants, hematopoietic recovery and
grade 2-4 aGVHD and cGVHD rates were not differ-
ent from that after BM transplants. However, there
was a survival advantage to transplantation of BM
compared to G-BM. The observed survival advantagePr
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Figure 1. Probabilities of OS after BM, G-BM, and PBPC transplanta-
tion from HLA-matched sibling donors for patients with severe aplastic
anemia adjusted for ATG use, performance score, and patient age. The
3-year probabilities are 80% (95% CI 76%-83%), 72% (95% CI 61%-80%),
and 76% (95% CI 68%-82%) after BM, G-BM, and PBPC transplants,
respectively.was primarily in patients younger than 21 years of age
at transplantation. To our knowledge, this is the first
report comparing transplant outcomes after G-BM
and BM for SAA.
Hematopoietic recovery rates were similar after G-
BM and PBPC transplants, but grade 2-4 aGVHD and
cGVHD were higher after PBPC transplants. Despite
higher GVHD rates after PBPC transplants, we did
not observe differences in survival after transplantation
of G-BM and PBPC. These findings are consistent
with the report by Morton and colleagues [10] where
patients were randomized to receive G-BM or PBPC
from their HLA-matched sibling. That trial included
patients with malignant and nonmalignant diseases;
rates of hematopoietic recovery and aGVHD were
similar, but cGVHD was higher after transplantation
of PBPC. Serody and colleagues [11], in their report
comparing transplantation of G-BM and PBPC for
malignant diseases, observed similar rates of hemato-
poietic recovery but higher aGVHD and cGVHD
after transplantation of PBPC. Consistent with our
observations, neither report showed differences in
OS after G-BM and PBPC transplants.
Compared to BM transplants, aGVHD and
cGVHD rates were higher after PBPC transplants.
However, this did not translate into higher mortality
in PBPC recipients. Reports that have shown lower
survival rates after PBPC transplants compared to
BM transplants have been in children with acute leuke-
mia or SAA and adults with good-risk chronic myeloid
leukemia (CML) [12,17,18]. In the current analysis,
51% (390 of 759) of the study population is younger
than 21 years, but only 12% (45 of 390) of patients
in this group received PBPC grafts. The relatively
small number of younger PBPC recipients in this
analysis may explain our inability to show significant
differences in survival after BM and PBPC
transplantation. Further, in the report that compared
transplantation outcomes after HLA-matched sibling
BM and PBPC transplants for SAA, in patients older
than 20 years, survival rates were not significantly
different after BM and PBPC transplant [12]. The ob-
served higher cGVHD after transplantation of PBPC
may yet translate into a survival disadvantage for these
patients, and only with longer follow-up of a larger co-
hort can this be examined satisfactorily. Survival after
transplantation was lower in patients with poor perfor-
mance score and older patients, and consistent
with other reports after transplantation for SAA. We
observed lower mortality risks with use of ATG, a sur-
rogate for the transplant conditioning regimen, cyclo-
phosphamide, and ATG. Over 95% of patients who
received ATG also received cyclophosphamide.
There are several limitations to consider when in-
terpreting data presented herein. Numbers of patients
who received G-BM transplants are relatively small
(approximately 80 patients), and transplant outcome
Table 3. Cause of Death
BM G-BM PBPC
Number (%) Number (%) Number (%)
Number of deaths 118 22 37
Cause of death
Graft failure 19 (16) 4 (18) 6 (16)
Infection 35 (30) 7 (32) 6 (16)
Interstitial pneumonitis 9 (8) 1 (5) 4 (11)
Adult respiratory distress
syndrome
2 (2) 0 1 (3)
Graft-versus-host disease 11 (9) 2 (9) 4 (11)
Organ failure 19 (16) 4 (18) 7 (19)
Second malignancy 0 1 (5) 2 (5)
Hemorrhage 14 (3) 2 (3) 7 (5)
Thromboembolism 2 (2) 1 (1) 0
Accidental death 2 (2) 0 0
Not reported 5 (4) 0 0
PBPC indicates peripheral blood progenitor cells; G-BM, granulocyte
bone marrow; BM, bone marrow.
Biol Blood Marrow Transplant 17:1018-1024, 2011 1023G-Mobilized BM for Aplastic Anemiadata on several hundreds of G-BM transplants are
needed to conclusively demonstrate equivalency
of G-BM transplants to BM transplants. The choice of
intervention (ie, graft source) was at the discretion of
the transplant center, and even though a controlled
analysis was performed adjusting for known risk fac-
tors, there may be unmeasured or unknown factors
that may influence transplant outcomes. We do not
collect dose and duration of G-CSF administration,
and both these factors are known to influence cell
dose collected [19,20]. Further, total nucleated cell
dose and CD341 dose at infusion were not collected
in a systemic manner and prevented us from exploring
an association between cell dose and transplant
outcomes.
These data suggest lower survival after transplanta-
tion of G-BM compared to transplantation of BM in
younger patients, and no advantage compared to trans-
plantation of PBPC. The higher cGVHD after PBPC
transplants warrants cautious use of this graft for SAA.
Therefore, BM grafts from HLA-matched sibling do-
nors are the preferred graft for patients with SAA.ACKNOWLEDGMENTS
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